Market Place
Sourcing Support
FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
31 Aug 2022 //
PRESS RELEASE
Enhertu strikes again with a PhIII success in another breast cancer population
16 Aug 2022 //
ENDPTS
Natco Pharma Ltd`s Generic Lapatinib Ditosylate Receives Approval In US
29 Sep 2020 //
FDA
No change to product information for breast cancer medicine Tyverb
27 Mar 2020 //
EMA
Puma Biotech cancer launch Nerlynx suffered in Q1.
10 May 2019 //
FIERCE PHARMA
Hetero launches Generic Lapatinib in India
15 Jan 2019 //
BIOSPECTRUM
Puma Biotech Announces Top Line Results of Phase III NALA Trial of Neratinib
18 Dec 2018 //
BUSINESSWIRE
ASLAN posts positive top-line varlitinib phase 2 data in breast cancer
16 Feb 2017 //
FIERCE PHARMA
Pfizer’s First-in-class Breast Cancer Therapy Wins EU Licensing
11 Nov 2016 //
PMLIVE
Swiss drugmaker Roche launches costliest cancer drugs in India
25 Nov 2015 //
ECONOMIC TIMES
Why Many Cancer Drugs Don`t Have To Cost So Much
25 Nov 2015 //
FORBES
U.S. cancer drug prices up to 3X higher than in Europe: Study
24 Sep 2015 //
FIERCE PHARMA
Exclusive: Americans overpaying hugely for cancer drugs - study
22 Sep 2015 //
REUTERS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.